Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00090324 · ClinicalTrials.gov registry record · Phase 3
Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Adolescent Patients With Schizophrenia
A Phase 3 study of Schizophrenia, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 249
- Enrollment target
- 20
- Study locations
NCT00090324: Completed Phase 3 study of Schizophrenia, sponsored by AstraZeneca.
NCT00090324 is a Phase 3 study of Schizophrenia that has completed, run by AstraZeneca. The registered enrollment target is 249 participants, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (14% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00090324, a Phase 3 study of Schizophrenia, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 249 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to demonstrate efficacy and safety of quetiapine fumarate (SEROQUEL) compared with placebo in the treatment of adolescent patients with schizophrenia.
Conditions Studied
Interventions
- DRUG quetiapine fumarate tablets
Study Locations (20)
California
- Research Site - Cerritos
- Research Site - Riverside
- Research Site - Sacramento
- Research Site - San Diego
Florida
- Research Site - Alamonte
- Research Site - Jacksonville
- Research Site - Miami
Ohio
- Research Site - Cincinnati
- Research Site - Cleveland
- Research Site - Lyndhurst
Illinois
- Research Site - Chicago
- Research Site - Oak Brook
Alabama
- Research Site - Dothan
Colorado
- Research Site - Denver
Kansas
- Research Site - Newton
Louisiana
- Research Site - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 249 participants |
| Start Date | 2004-09 |
| Est. Completion | 2007-06 |
| Phase | Phase 3 |
What the finished NCT00090324 record still lists
NCT00090324 is an interventional study that assigns participants to a tested intervention. The registered 249 participants enrollment target is mid-sized for trials with a published cap, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (14% higher).
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which quetiapine fumarate tablets is the first listed.
NCT00090324 names 20 study sites across 12 states, led by California, Florida, Ohio.
Frequently Asked Questions
What is clinical trial NCT00090324 about?
NCT00090324 is a clinical study titled "Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Adolescent Patients With Schizophrenia". The purpose of this study is to demonstrate efficacy and safety of quetiapine fumarate (SEROQUEL) compared with placebo in the treatment of adolescent patients with schizophrenia.
What is the current status of trial NCT00090324?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 249 participants. The study started on 2004-09. Estimated completion is 2007-06.
What conditions does trial NCT00090324 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT00090324?
The interventions under investigation include: quetiapine fumarate tablets (DRUG).
Who is sponsoring clinical trial NCT00090324?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00090324 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00090324's enrollment target sits among peer trials
249 77th of 315 higher than 239 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
RECRUITING · Phase 3
-
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
RECRUITING · Phase 3
-
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
RECRUITING · Phase 3
-
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
RECRUITING · Phase 3
-
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04628767 · 249 participants · Phase 2
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
- NCT05834907 · 249 participants · NA
Hands and Hearts Together
- NCT06067555 · 249 participants · Early Phase 1
Intradermal Influenza Vaccination
- NCT06588478 · 249 participants · Phase 2
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia